Biomarkers and Dysplastic Respiratory Epithelium
- Determine intermediate biomarkers of premalignant respiratory epithelial lesions, such
as genetic mutations or altered growth factor expression, in patients with dysplasia of
the respiratory epithelium or lung cancer, head and neck cancer, or aerodigestive tract
- Establish a tissue repository of normal and dysplastic respiratory epithelium from
endobronchial forceps and brush biopsy tissue from these patients and from normal
OUTLINE: Patients are stratified according to presence of extensive and severe dysplasia of
the respiratory epithelium (yes vs no).
Participants undergo sputum cytology, white-light (with or without fluorescence)
bronchoscopy, and endobronchial biopsies. Participants also undergo endobronchial brushings
and bronchial secretion collection and possibly bronchoalveolar lavage. Collected samples
are processed by hematoxylin, eosin, and immunohistochemical staining and analyzed for
specific biomarkers. Unused samples are stored in the tissue bank.
PROJECTED ACCRUAL: A total of 330 participants will be accrued for this study.
Time Perspective: Prospective
Genetic mutations or altered growth factor expression
After study has completed
York E. Miller, MD
University of Colorado, Denver
United States: Institutional Review Board
|University of Colorado Cancer Center at UC Health Sciences Center||Aurora, Colorado 80045|